InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Explore the full record of transactions filed by Haviland Kate, Chief Operating Officer. Director active across 1 companies, notably Blueprint Medicines Corp. Aggregated, 8 filings have been published. Total volume traded: €93k. The latest transaction was disclosed on 3 March 2022 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations8 total
€93,2331,719 shares@ €54.23733.5% of flow
Common Stock
SEC:0001415889-22-002733:0·
040,000 shares0
Common Stock
SEC:0001415889-22-002440:0·
€31,8691,000 shares@ €31.869334.4% of flow
Common Stock
SEC:0001179110-21-010988·
€31,8691,000 shares@ €31.869311.4% of flow
Common Stock
SEC:0001179110-21-010988:0·
€30,5201,000 shares@ €30.519933.0% of flow
Common Stock
SEC:0001179110-21-008782·
€30,5201,000 shares@ €30.519911.0% of flow
Common Stock
SEC:0001179110-21-008782:0·
€30,2211,000 shares@ €30.220732.6% of flow
Common Stock
SEC:0001179110-21-007172·
€30,2211,000 shares@ €30.220710.9% of flow
Common Stock
SEC:0001179110-21-007172:0·
8 of 8 declarations
About Haviland Kate
Kate Haviland is the Chief Operating Officer at Blueprint Medicines Corp. She is responsible for managing operations and implementing the company's strategy. Her expertise is crucial in ensuring growth and operational efficiency within Blueprint Medicines.
